China accepts CANbridge’s NDA for CAN108 to treat cholestatic pruritus in PFIC
The NDA has been submitted based data from the randomised Phase III MARCH PFIC study of LIVMARLI. A total of 93 patients with various generic PFIC subtypes including
Global healthcare holding company OSR Holdings has entered into a memorandum of understanding (MoU) with SillaJen, a South Korea-based biotechnology company with a pipeline of immuno-oncology drug candidates.
CHMP also recommended approval of the anti-programmed death receptor-1 (PD-1) therapy. It recommended approval of KEYTRUDA along with fluoropyrimidine- and platinum-containing chemotherapy as first-line treatment for locally advanced
The contract was signed through TaiGen’s subsidiary company TaiGen Biotechnology. Considering the competitiveness of the pharmaceutical market as well as concerns about proprietary information, the companies did not
CST-3056 is an alpha-1A adrenoceptor (α1A-AR) agonist, and is still in preclinical development. Alzheimer’s Drug Discovery Foundation co-founder and chief science officer Howard Fillit said: “Alpha-1A adrenoceptors are